<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="publisher-id">Neuropsychiatric Disease and Treatment</journal-id><journal-title-group><journal-title>Neuropsychiatric Disease and Treatment</journal-title></journal-title-group><issn pub-type="ppub">1176-6328</issn><issn pub-type="epub">1178-2021</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19590732</article-id><article-id pub-id-type="pmc">2706569</article-id><article-id pub-id-type="publisher-id">ndt-5-369</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bobo</surname><given-names>William V</given-names></name><xref ref-type="corresp" rid="c1-ndt-5-369"/></contrib><contrib contrib-type="author"><name><surname>Shelton</surname><given-names>Richard C</given-names></name></contrib><aff id="af1-ndt-5-369">Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA</aff></contrib-group><author-notes><corresp id="c1-ndt-5-369">Correspondence: William V Bobo, 1500 25th Ave South, Suite 2200, Village at Vanderbilt, Nashville, TN 37212, USA, Tel +1 615 327 7049, Fax +1 615 327 7093, email
<email>william.v.bobo@vanderbilt.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub--><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>7</month><year>2009</year></pub-date><volume>5</volume><fpage>369</fpage><lpage>383</lpage><permissions><copyright-statement>&#x000a9; 2009 Bobo and Shelton, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2009</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Treatment-resistant depression (TRD) is a common occurrence in clinical practice. Up to 30% of patients with major depression do not respond to conventional antidepressant treatment, while a significantly greater number of patients experience only partial symptom reduction. Numerous strategies may be applied by the practicing clinician to overcome limitations in the effectiveness of antidepressant monotherapy, including combining drug treatment with evidence-supported psychotherapies, combining antidepressants (combination pharmacotherapy), and combining antidepressants with other non-antidepressant psychotropic medications (augmentation treatment). One such augmentation strategy, the combination of the selective serotonin reuptake inhibitor, fluoxetine (FLX), with the atypical antipsychotic drug, olanzapine (OLZ), is supported by the results of four randomized, double-blind, acute phase studies of patients who had responded inadequately to antidepressant monotherapy. In each study, the FLX/OLZ combination caused rapid reduction in Montgomery-Asberg Depression Rating scale scores, with two of the four studies showing significantly greater improvement than antidepressant monotherapy at study endpoint. Effects of the FLX/OLZ combination were strongest in cases where failure to respond to two antidepressants prior to randomization was established during the current depressive episode. The FLX/OLZ combination was well-tolerated; however, body weight gain and increases in prolactin were greater than that of the antidepressant monotherapy groups, and were comparable to that of OLZ monotherapy. While effective during acute-phase treatment, questions remain regarding the long-term efficacy and safety of FLX/OLZ relative to antidepressant monotherapy and other combination strategies. Efforts aimed at determining the placement of FLX/OLZ among the available options for addressing TRD are limited by lack of comparison and sequential treatment studies. Important aspects of study design and directions for future research are discussed.</p></abstract><kwd-group><kwd>olanzapine</kwd><kwd>fluoxetine</kwd><kwd>combination therapy</kwd><kwd>major depression</kwd><kwd>treatment resistance</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In the last two decades, there has been a marked increase in the number of antidepressant medications available for the treatment of major depressive disorder (MDD). In spite of this, it has become increasingly evident that the effectiveness of antidepressant monotherapy for MDD is much more modest than what was once believed. For example, a recent meta-analysis of all published double-blind placebo controlled antidepressant trials reported an antidepressant response rate of 53%.<xref ref-type="bibr" rid="b1-ndt-5-369">1</xref> Although this rate of response was significantly greater than the placebo response rate (36%, <italic>P</italic> &#x0003c; 0.05), these results have challenged the widely accepted anticipated response rates of 60% to 70% reported in prior reviews of controlled studies.<xref ref-type="bibr" rid="b2-ndt-5-369">2</xref></p><p>Rates of acute and sustained symptom remission on antidepressant monotherapy are even lower, both under ideal treatment conditions that characterize randomized controlled trials, and in actual clinical treatment settings.<xref ref-type="bibr" rid="b3-ndt-5-369">3</xref>&#x02013;<xref ref-type="bibr" rid="b5-ndt-5-369">5</xref> For instance, only about 30% of patients achieved clinical remission in the first phase of the landmark Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study after 12 weeks of citalopram monotherapy.<xref ref-type="bibr" rid="b6-ndt-5-369">6</xref> Only about 70% of patients achieved remission after multiple rounds of medications or cognitive therapy, and the majority of patients relapsed within the first year following remission.<xref ref-type="bibr" rid="b7-ndt-5-369">7</xref> The importance of this point rests in the fact that the persistence of residual depressive symptoms is associated with substantial disability and increased risk of a full depressive relapse, even among patients who achieve a positive antidepressant response and remain in active treatment.<xref ref-type="bibr" rid="b8-ndt-5-369">8</xref>,<xref ref-type="bibr" rid="b9-ndt-5-369">9</xref> As such, the majority of antidepressant-treated patients with major depression either fail to improve meaningfully or experience positive but only partial improvement. Clearly, there is an urgent need to develop safe and more effective treatments for major depressive disorder (MDD).</p><p>Until such treatments become available, numerous strategies may be applied by the practicing clinician to overcome limitations in the effectiveness of antidepressant monotherapy. In broad terms, these include combining drug treatment with evidence-supported psychotherapies,<xref ref-type="bibr" rid="b10-ndt-5-369">10</xref> combining antidepressants with different pharmacological profiles (combination pharmacotherapy), and combining antidepressants with psychotropic medications that are not antidepressants (augmentation treatment).<xref ref-type="bibr" rid="b11-ndt-5-369">11</xref>,<xref ref-type="bibr" rid="b12-ndt-5-369">12</xref> One such augmentation treatment approach is the combination of antidepressants with atypical antipsychotic drugs. There is now controlled evidence supporting the short-term effectiveness of atypical antipsychotic augmentation of antidepressants, including cases of difficult to treat MDD with and without psychotic features.<xref ref-type="bibr" rid="b13-ndt-5-369">13</xref>&#x02013;<xref ref-type="bibr" rid="b15-ndt-5-369">15</xref> In addition, one atypical antipsychotic drug, aripiprazole, has a US Food and Drug Administration (FDA) indication as an adjunctive therapy for suboptimal antidepressant response in patients with MDD,<xref ref-type="bibr" rid="b16-ndt-5-369">16</xref> and one selective serotonin reuptake inhibitor (SSRI)/atypical antipsychotic combination (fluoxetine + olanzapine) is FDA approved for acute bipolar depression.<xref ref-type="bibr" rid="b17-ndt-5-369">17</xref> Enthusiasm for this approach is tempered by a lack of long-term effectiveness data, as well as long-term metabolic safety and tolerability concerns for many of these agents. This review is focused on the therapeutic rationale for and clinical evidence supporting the combination of fluoxetine and olanzapine for treatment-resistant MDD (TRD). Characteristics and implications of key design issues in each of the reviewed studies will be emphasized.</p></sec><sec><title>Mechanisms of action</title><sec><title>Neurotransmitter dysfunction in major depression</title><p>A substantial body of evidence indicates that dysfunction in serotonin (5-hydroxytryptamine, 5-HT), norepinephrine (NE) and, to a lesser degree, dopamine (DA) neurotransmission are involved in the pathophysiology of major depression,<xref ref-type="bibr" rid="b18-ndt-5-369">18</xref>&#x02013;<xref ref-type="bibr" rid="b20-ndt-5-369">20</xref> and that intact 5-HT and NE neurotransmitter systems are needed in order to maintain positive clinical response to antidepressant medications. By now, it is also apparent that early theories that sought to explain the signs and symptoms of major depression solely on the basis of 5-HT and NE depletion have not provided a unifying neurobiological theory explaining why major depression occurs or how antidepressants exert their therapeutic effects. Nevertheless, the monoaminergic neurotransmitter systems have served as the most important pharmacological targets from antidepressant drug development over the last four decades.<xref ref-type="bibr" rid="b21-ndt-5-369">21</xref> Nearly all currently available antidepressant drugs act as potentiators of monoamine neurotransmission, either by inhibition of enzymes needed for monoamine degradation, or by blocking monoamine reuptake sites.</p><p>In recent years, a more sophisticated understanding of the pathophysiology of major depression has emerged that focuses on dysregulation of 5-HT and NE transmission rather than monoamine depletion, per se. Abnormalities in the functional activity of numerous brain regions have been identified in depressed patients using functional neuroimaging, including cortical and limbic structures that are critical for regulation of mood, emotional processing, cognitive and psychomotor functioning, and motivation,<xref ref-type="bibr" rid="b22-ndt-5-369">22</xref>&#x02013;<xref ref-type="bibr" rid="b24-ndt-5-369">24</xref> all common symptoms of depression. Importantly, each of these regions receive serotonergic, noradrenergic and/or dopaminergic projections,<xref ref-type="bibr" rid="b25-ndt-5-369">25</xref> and abnormalities in several of these regions identified on neuroimaging have been shown to resolve following treatment with antidepressants that potentiate 5-HT and/or NE neurotransmission.<xref ref-type="bibr" rid="b26-ndt-5-369">26</xref>&#x02013;<xref ref-type="bibr" rid="b29-ndt-5-369">29</xref></p></sec><sec><title>Limitations of fluoxetine monotherapy</title><p>Monoamine neurotransmission in these key brain regions is tightly regulated, in part, by functional activity of several critical postsynaptic neuroreceptors that are not acted upon directly by SSRIs and other first-line antidepressants. Fluoxetine (FLX) and other SSRIs occupy 5-HT reuptake pumps with relatively high affinity and specificity; however, their pharmacological activity is limited, for all practical purposes, to reuptake pump blockade.<xref ref-type="bibr" rid="b30-ndt-5-369">30</xref>,<xref ref-type="bibr" rid="b31-ndt-5-369">31</xref> This poses three potential limitations that may result in a lack of meaningful clinical response to monotherapy with FLX for some patients. First, FLX does not act as a pharmacological agonist and cannot directly activate postsynaptic receptors that are important for the control of monoamine functioning in the central nervous system (CNS). Instead, FLX is dependent almost entirely on intact presynaptic serotonergic functioning.<xref ref-type="bibr" rid="b32-ndt-5-369">32</xref> Second, FLX has only negligible effects on NE and DA reuptake, and does not directly enhance noradrenergic or dopaminergic neurotransmission.<xref ref-type="bibr" rid="b30-ndt-5-369">30</xref> Furthermore, continuous SSRI treatment is associated with suppression of locus coeruleus firing,<xref ref-type="bibr" rid="b33-ndt-5-369">33</xref>&#x02013;<xref ref-type="bibr" rid="b35-ndt-5-369">35</xref> resulting in decreased NE transmission. This is believed to occur as a consequence of enhanced activation of excitatory postsynaptic 5-HT2A receptors located on inhibitory GABAergic interneurons that synapse with NE neurons.<xref ref-type="bibr" rid="b36-ndt-5-369">36</xref> Third, SSRIs have been shown to suppress ventral tegmental area activity, and therefore reduce DA neurotransmission,<xref ref-type="bibr" rid="b37-ndt-5-369">37</xref>,<xref ref-type="bibr" rid="b38-ndt-5-369">38</xref> possibly by a 5-HT2C dependent mechanism.<xref ref-type="bibr" rid="b39-ndt-5-369">39</xref>&#x02013;<xref ref-type="bibr" rid="b41-ndt-5-369">41</xref> Thus, FLX and other SSRIs may not be able to fully optimize central monoaminergic functioning as stand-alone therapies. These limitations cannot be overcome by increases in medication dosage alone.</p></sec><sec><title>Augmentation with atypical antipsychotics: focus on olanzapine</title><p>The atypical antipsychotics are a pharmacologically heterogenous group of drugs. Although each is associated with a unique profile of neuroreceptor binding activity, all share the properties of high-potency postsynaptic 5-HT2A antagonism with relatively lower potency dopamine D2 receptor antagonism (or D2 partial agonist effects, in the case of aripiprazole). Importantly, the atypical antipsychotic drug, olanzapine (OLZ), is pharmacologically active at other neuroreceptors that are important for optimizing central monoamine functioning (<xref ref-type="table" rid="t1-ndt-5-369">Table 1</xref>). As such, adjunctive therapy with OLZ may be a practical means of overcoming many of the mechanistic limitations of FLX monotherapy, and improving clinical response to FLX in patients with treatment resistant major depression.</p><p>For example, 5-HT2A blockade results in numerous effects that are relevant to the activity of FLX. In the presence of 5-HT reuptake inhibition, 5-HT2A receptor antagonism has been shown to enhance 5-HT and NE release in rodents.<xref ref-type="bibr" rid="b42-ndt-5-369">42</xref> In preclinical models, chronic administration of FLX alone suppressed locus coeruleus neuronal activity while acutely administered OLZ significantly increased locus coeruleus firing.<xref ref-type="bibr" rid="b43-ndt-5-369">43</xref> The combination of FLX + OLZ, however, resulted in enhanced locus coeruleus firing during both acute and chronic administration.<xref ref-type="bibr" rid="b43-ndt-5-369">43</xref> Increased NE release may be predicted by antagonism of the aforementioned 5-HT2A dependent reduction in NE neuronal firing, while increased NE release may then enhance 5-HT neuronal firing via activation of postsynaptic &#x003b1;-1 adrenergic receptors in the raphe nuclei.<xref ref-type="bibr" rid="b42-ndt-5-369">42</xref> In addition, OLZ-associated postsynaptic 5-HT2C antagonism and 5-HT1A activation have also been shown to increase NE release in the prefrontal cortex.<xref ref-type="bibr" rid="b44-ndt-5-369">44</xref> Thus, the combination of FLX + OLZ may result in a greater degree of serotonergic activity than would be expected with FLX alone, and may also reverse FLX-associated NE suppression.</p><p>Interactions at serotonin receptors also have important effects on DA neurotransmission. Blockade of 5-HT2A and 5-HT6 receptors, combined with weak D2 receptor antagonism, have both been shown to enhance DA release to a greater degree than blockade of either receptor alone.<xref ref-type="bibr" rid="b45-ndt-5-369">45</xref>,<xref ref-type="bibr" rid="b46-ndt-5-369">46</xref> In addition to increasing NE efflux, OLZ effects on 5-HT2C and 5-HT1A receptors have been shown to increase DA release in the frontal cortex and nucleus accumbens,<xref ref-type="bibr" rid="b44-ndt-5-369">44</xref>,<xref ref-type="bibr" rid="b47-ndt-5-369">47</xref> brain regions that are tied to cognitive functioning and motivational drive.<xref ref-type="bibr" rid="b48-ndt-5-369">48</xref> Clinically, the 5-HT2A antagonists, trazodone and nefazodone, and the 5-HT1A partial agonist, gepirone, have all shown antidepressant effects in clinical trials.<xref ref-type="bibr" rid="b49-ndt-5-369">49</xref>&#x02013;<xref ref-type="bibr" rid="b51-ndt-5-369">51</xref> Augmentation of FLX with OLZ may therefore provide a means of enhancing DA activity in brain regions implicated in the pathophysiology of major depression that would not be possible with FLX alone, an effect that may be strong enough to overcome FLX-associated suppression of central DA activity and improve antidepressant response.</p><p>Finally, there has been considerable interest in the role of brain derived neurotrophic factor (BDNF), one of a number of neurotrophic factors involved in neuronal maintenance and survival,<xref ref-type="bibr" rid="b52-ndt-5-369">52</xref> in the both pathogenesis of major depression and the clinical response to antidepressants.<xref ref-type="bibr" rid="b53-ndt-5-369">53</xref> BDNF has been shown to play an important role in the susceptibility of depression-prone patients to the negative effects of stress.<xref ref-type="bibr" rid="b54-ndt-5-369">54</xref> In post-mortem brains of depressed patients, low levels of hippocampal and prefrontal BDNF have been documented.<xref ref-type="bibr" rid="b53-ndt-5-369">53</xref> Abnormally low levels of serum BDNF have also been found in patients with major depression.<xref ref-type="bibr" rid="b55-ndt-5-369">55</xref> It is noteworthy that long-term exposure to FLX and other antidepressants has been shown to increase BDNF production,<xref ref-type="bibr" rid="b56-ndt-5-369">56</xref> and that stress-induced reduction in levels of BDNF and Bcl-2, another neurotrophic factor, may be blocked with long-term treatment with OLZ.<xref ref-type="bibr" rid="b57-ndt-5-369">57</xref> These results suggest that the combination of FLX + OLZ may have synergistic effects on neurotrophin activity, thereby providing an alternative mechanism by which OLZ may enhance the clinical antidepressive effects of FLX.</p></sec></sec><sec><title>Efficacy in clinical trials</title><sec sec-type="results"><title>Results of acute phase studies in TRD</title><p>Five randomized, controlled trials have investigated the effect of OLZ augmentation of FLX in acute phase TRD, two of which were publised in a single paper by Thase et al.<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> All studies were generally similar in design (<xref ref-type="fig" rid="f1-ndt-5-369">Figure 1</xref>). Patients with non-psychotic major depression and a prior history of antidepressant failure (variously defined, as discussed below) received an open-label trial of antidepressant monotherapy during a pre-randomization (lead-in) phase. Individuals who failed to achieve a pre-specified threshold of symptom response during this open-label treatment phase were then eligible for randomization to double-blind acute phase treatment with OLZ + FLX or one of several active control conditions, including continuation treatment with the lead-in phase antidepressant. The design features and key results of the pre-randomization and randomized acute treatment phases of each study are summarized in <xref ref-type="table" rid="t2-ndt-5-369">Tables 2</xref> and <xref ref-type="table" rid="t3-ndt-5-369">3</xref>, respectively.</p><p>The first randomized, controlled study of atypical antipsychotic drug augmentation of antidepressants for TRD compared the effects of FLX + OLZ, FLX monotherapy (FLX + placebo) and OLZ monotherapy (OLZ + placebo).<xref ref-type="bibr" rid="b58-ndt-5-369">58</xref> There is a paucity of long-term efficacy data for the use of FLX/OLZ combination therapy for TRD. In one single-arm study,<xref ref-type="bibr" rid="b67-ndt-5-369">67</xref> a mixed sample of 560 patients with TRD (N =145, defined as having history of past failure to respond to at least two trials of antidepressant treatment using agents of different pharmacological classes) and non-treatment refractory major depression (non-TRD, N =407) received an open-label trial. Treatment resistance was confirmed by failure to achieve a partial response to open-label FLX (up to 60 mg/day) during the pre-randomization lead-in phase. Twenty-eight non-responders were then randomly assigned in a double-blind fashion to one of the three acute phase treatment conditions (see <xref ref-type="table" rid="t3-ndt-5-369">Table 3</xref> for mean doses). Continuation of FLX monotherapy yielded no further improvement in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS),<xref ref-type="bibr" rid="b59-ndt-5-369">59</xref> the Hamilton Depression Rating Scale (HAM-D)<xref ref-type="bibr" rid="b60-ndt-5-369">60</xref> and the Clinical Global Impressions-Depression subscale (CGI-D),<xref ref-type="bibr" rid="b61-ndt-5-369">61</xref> while OLZ monotherapy achieved a modest benefit over FLX alone. The FLX/OLZ combination resulted in significantly greater improvement in depressive symptoms than FLX or OLZ alone (<xref ref-type="table" rid="t3-ndt-5-369">Table 3</xref>). The proportion of patients who achieved positive clinical response (&#x02265;50% improvement in MADRS scores at endpoint) was greater for the FLX/OLZ group (60%) compared with OLZ (0%) and FLX (10%) monotherapy groups. Pairwise comparisons of the proportion of those achieving positive clinical response were significant only for FLX/OLZ vs OLZ monotherapy, favoring combination therapy.</p><p>Four larger-scale randomized, double-blind multi-center studies investigating the effects of FLX/OLZ combination therapy were then completed.<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref>&#x02013;<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> In the first study,<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> 500 non-psychotically depressed patients with a prior history of failure to respond to a &#x02265;4 week trial of SSRI treatment and prospective failure of open-label NTP (<xref ref-type="table" rid="t2-ndt-5-369">Table 2</xref>) were randomized to one of four treatment groups for the 8-week acute phase study: FLX + OLZ, FLX monotherapy (FLX + placebo), OLZ monotherapy (OLZ + placebo), or continuation treatment with NTP (+ placebo) at the same dosage used during the pre-randomization lead-in phase (<xref ref-type="table" rid="t3-ndt-5-369">Table 3</xref>). The OLZ/FLX combination produced rapid antidepressant effect and statistically superior improvement in MADRS scores compared with all monotherapy groups through the first four weeks of treatment; however, there were no significant differences between these groups at study endpoint. There were also no significant differences between the FLX + OLZ, FLX monotherapy, OLZ monotherapy, or NTP monotherapy groups in Hamilton Anxiety Scale (HAM-A)<xref ref-type="bibr" rid="b65-ndt-5-369">65</xref> or Clinical Global Impressions-Illness Severity subscale scores,<xref ref-type="bibr" rid="b61-ndt-5-369">61</xref> or rates of categorical treatment response (27.5%, 28.9%, 19.3%, and 30.3%, respectively) or remission (16.9%, 13.3%, 12.9%, and 18.2%, respectively), at study endpoint.</p><p>The second large-scale study compared the clinical effects of OLZ/FLX combination,<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> FLX monotherapy, OLZ monotherapy, and VLFX monotherapy over 12 weeks in a cohort of non-psychotically depressed patients (N = 483) with a past history of failure to respond to a &#x02265;6 week therapeutic SSRI trial and prospective failure of an open-label lead-in trial of VLFX (<xref ref-type="table" rid="t2-ndt-5-369">Table 2</xref>). Again, there was significant early improvement associated with OLZ/FLX treatment, and significantly greater improvement in MADRS scores for OLZ/FLX over VLFX monotherapy (first 6 weeks only) and FLX monotherapy (first 11 weeks only). At study endpoint, there was no evidence of a FLX/OLZ advantage over any antidepressant monotherapy group (<xref ref-type="table" rid="t3-ndt-5-369">Table 3</xref>). This included no significant differences between FLX + OLZ, FLX monotherapy, OLZ monotherapy, and VLFX monotherapy groups in rates of categorical treatment response (43.3%, 33.9%, 25.4%, and 50.0%, respectively) or remission (29.9%, 17.9%, 13.6%, and 22.4%, respectively) at study endpoint.</p><p>The final two studies were of identical design and were run concurrently (Study 1 and Study 2). Results were reported separately and as pooled data.<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> Both studies were randomized, double-blind 8-week comparisons of FLX/OLZ combination therapy, FLX monotherapy (FLX + placebo) and OLZ monotherapy (OLZ + placebo) in a cohort of patients with non-psychotic major depression (N = 605, pooled data set). Eligibility was based on a past history of SSRI failure during the current depressive episode only, followed by prospective failure of an 8-week open-label FLX (50 mg/day) lead-in trial. In Study 1, there was no evidence of a superior antidepressive effect for FLX/OLZ combination treatment over either monotherapy group. However, in Study 2, the FLX/OLZ combination resulted in significantly greater improvement in MADRS scores, and in categorical response and remission rates, compared with both monotherapy groups at study endpoint. The pooled analysis of both projects revealed significantly greater improvement in MADRS scores, higher rates of categorical response (FLX + OLZ, 40.4%; FLX, 29.6%; OLZ, 25.9%) and remission (FLX + OLZ, 27.3%; FLX 16.7%; OLZ 14.7%), and shorter time required for 25% of patients to achieve therapeutic responder status (FLX + OLZ, 30 days; FLX, 55 days; OLZ, 53 days), compared with both monotherapy groups (<xref ref-type="table" rid="t3-ndt-5-369">Table 3</xref>). There were also advantages for FLX/OLZ over both antidepressant monotherapies in family and leisure functioning as measured by the Sheehan Disability Scale.<xref ref-type="bibr" rid="b66-ndt-5-369">66</xref> There was no statistically significant advantage observed for work functioning.</p></sec><sec sec-type="results"><title>Results of long-term studies</title><p>There is a paucity of long-term efficacy data for the use of FLX/OLZ combination therapy for TRD. In one single-arm study,<xref ref-type="bibr" rid="b67-ndt-5-369">67</xref> a mixed sample of 560 patients with TRD (N =145, defined as having history of past failure to respond to at least two trials of antidepressant treatment using agents of different pharmacological classes) and non-treatment refractory major depression (non-TRD, N =407) received an open-label trial FLX/OLZ (mean modal dose = 46.1 &#x000b1; 20.7 mg/day of FLX/7.5 &#x000b1; 3.5 mg/day of OLZ) for up to 76 weeks. There was a significant reduction in MADRS and CGI-S subscale scores as early as 0.5 weeks, followed by strong and continuous reductions in these measures througout the remainder of the study in both TRD and non-TRD patients. At study endpoint, 61.6% of patients met categorical response criteria (&#x02265;50% reduction in MADRS scores), and 56.3% of patients achieved remission (MADRS scores of &#x02264;8 on two consecutive visits. Higher remission rates (60.7% vs 44.1%) and shorter time to remission were observed in the non-TRD compared with TRD sample. These results were tempered by relatively high droput rates. Only 177 (31.6%) of patients completed 52 weeks of treatment, and only 143 (25.5%) of patients completed the 76-week trial. In addition, of the patients who achieved remission, 12.1% of non-TRD and 25.0% of TRD patients relapsed (defined as a MADRS score of &#x02265;16 at any two visits following remission). More long-term studies are needed.</p></sec><sec><title>Tolerability and safety</title><p>Safety and tolerability results across each of the acute-phase studies are summarized in <xref ref-type="table" rid="t4-ndt-5-369">Table 4</xref>. Rates of discontinuation due to treatment-emergent adverse effects (TEAEs) were greatest for FLX/OLZ- and OLZ monotherapy-treated patients. Because those who did not tolerate lead-in antidepressant medication were dropped prior to randomization, discontinuation rates tended to be lowest for drugs that were utilized during the lead-in phase and were continued during the double-blind treatment period.</p><p>Increases in body weight, total non-fasting cholesterol and serum prolactin (PRL) levels were greatest for the FLX/OLZ and OLZ groups. There was little change from baseline in any of these measures for the antidepressant monotherapy groups during double-blind treatment. The magnitude of increases in these measures between FLX/ OLZ and OLZ groups was generally similar. However, increases in total cholesterol were significantly greater for FLX + OLZ vs OLZ monotherapy in a pooled analysis of data from the 5 acute phase studies reviewed above.<xref ref-type="bibr" rid="b76-ndt-5-369">76</xref> There were no significant differences for change in triglyceride levels between these two groups in the Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> study. There were no significant between groups differences in baseline to endpoint change in non-fasting glucose in the studies by Shelton et al<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> and Thase et al;<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> however, in both studies, the numerical increases in non-fasting glucose levels were greatest in the FLX/OLZ and OLZ groups relative to the antidepressant monotherapy groups. Similar increases in weight (+ 5.6 &#x000b1; 6.6 kg) and non-fasting glucose levels were reported in the long-term open-label study by Corya et al<xref ref-type="bibr" rid="b67-ndt-5-369">67</xref></p><p>Extrapyramidal side effects (EPS) were measured using the Simpson-Angus Scale (SAS),<xref ref-type="bibr" rid="b68-ndt-5-369">68</xref> Barnes Akathisia Scale (BARS),<xref ref-type="bibr" rid="b69-ndt-5-369">69</xref> and the Abnormal Involuntary Movement Scale (AIMS)<xref ref-type="bibr" rid="b70-ndt-5-369">70</xref> in each of the reviewed studies. There were no significant between groups differences in EPS measures in the Shelton et al <xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> study. There were no significant changes in these measures from baseline in any of the treatment groups in the Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> study, or in the FLX/OLZ group in the Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> study. EPS measures for the FLX/OLZ group were reported as being similar to that of the OLZ group. In the long-term open-label study by Corya et al<xref ref-type="bibr" rid="b67-ndt-5-369">67</xref> there were no significant increases in SAS, BARS or AIMS scores between baseline and the 76-week study endpoint. In the only study that assessed PRL response, FLX/OLZ was associated with significantly greater increases in PRL concentration than FLX, OLZ or NTP monotherapy.<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref></p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Clinical issues</title><p>TRD is a common occurrence in clinical practice, and poses numerous challenges for the practicing clinician. While atypical antipsychotic augmentation of antidepressant medication was shown to be an effective strategy for patients with TRD in a recent meta-analysis of 10 randomized, double-blind, placebo controlled trials,<xref ref-type="bibr" rid="b14-ndt-5-369">14</xref> their exact place within the m&#x000e9;lange of therapeutic options for managing TRD has not been precisely defined. For this to be determined, data from sequential treatment studies and/or head-to-head comparisons would be needed. The largest sequential investigation of therapeutic options in TRD to date, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, did not investigate the effects of atypical antipsychotic augmentation. Data from head-to-head comparison trials between FLX/OLZ and other interventions for TRD are not yet available. Nevertheless, based on clinical trial results that are currently available, the strongest clinical evidence supporting a role for atypical antipsychotic drugs as augmenters of antidepressants in TRD exists for olanazapine, quetiapine and aripiprazole, at least for short-term, acute phase treatment.<xref ref-type="bibr" rid="b13-ndt-5-369">13</xref>,<xref ref-type="bibr" rid="b14-ndt-5-369">14</xref>,<xref ref-type="bibr" rid="b71-ndt-5-369">71</xref>&#x02013;<xref ref-type="bibr" rid="b74-ndt-5-369">74</xref> Of these, only aripiprazole is currently approved for this indication.</p><p>Our review of the literature, which focused on the effects of OLZ augmentation of FLX in TRD, also supports the short-term efficacy of this strategy, is consistent with a prior narrative review of FLZ + OLZ in TRD.<xref ref-type="bibr" rid="b75-ndt-5-369">75</xref> Effectiveness of this combination appears to be particularly strong for those with an inadequate SSRI response and treatment resistance in the current depressive episode. Focusing on this sub-population of patients has at least two advantages. First, the decision to augment antidepressant therapy with OLZ in actual clinical practice would be based on poor treatment response to antidepressant monotherapy in the current depressive episode, rather than having a history of poor antidepressant response in prior depressive episodes. Next, the consideration of only those subjects who met treatment failure criteria during the current depressive episode would guard against the inclusion of less treatment resistant cases in studies that focus specifically on intervention effects in TRD. This would result in a sample that is more representative of the TRD population encountered in clinical practice. Patients with TRD, defined in this more stringent manner, would also have a greater likelihood of achieving a more favorable clinical response to antidepressant augmentation compared with monotherapy. This position is supported by results of Shelton et al,<xref ref-type="bibr" rid="b58-ndt-5-369">58</xref> Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> and the pooled analysis by Trivedi et al<xref ref-type="bibr" rid="b76-ndt-5-369">76</xref> which focused on patients with TRD based on the current depressive episode only. All showed stronger effects of FLX/OLZ augmentation relative to antidepressant monotherapy than did individual large-scale studies that used a less stringent definition of TRD.<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref>,<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref></p><p>Available evidence of effectiveness FLX + OLZ in TRD is similar to the published data describing the combination&#x02019;s effectiveness for the short-term acute-phase treatment of depression in patients with bipolar I disorder.<xref ref-type="bibr" rid="b77-ndt-5-369">77</xref>,<xref ref-type="bibr" rid="b78-ndt-5-369">78</xref> In two randomized, controlled studies, FLX + OLZ resulted in greater 8-week improvement in depressive symptomatology compared with placebo and OLZ monotherapy,<xref ref-type="bibr" rid="b79-ndt-5-369">79</xref> and greater 7-week improvement than lamotrigine.<xref ref-type="bibr" rid="b78-ndt-5-369">78</xref> In addition, combination therapy with FLX + OLZ was associated with higher remission rates than placebo or OLZ monotherapy,<xref ref-type="bibr" rid="b77-ndt-5-369">77</xref> and a similar remission rate as lamotrigine.<xref ref-type="bibr" rid="b78-ndt-5-369">78</xref> In one small placebo-controlled study comparing the effects of FLX + OLZ, OLZ monotherapy, FLX monotherapy and placebo in depressed patients with bipolar I or II disorder, there were significant reductions in depressive symptoms for the entire cohort; however, the study was under-powered to detect differences between treatment groups.<xref ref-type="bibr" rid="b80-ndt-5-369">80</xref> In published studies of bipolar depressed patients, FLX + OLZ was generally well tolerated, with limited safety data suggesting that FLX + OLZ combination therapy was associated with weight gain and lipid and prolactin level elevation similar to that of OLZ monotherapy. As is the case with TRD, long-term safety and effectiveness data in bipolar patients are generally lacking. FLX + OLZ combination therapy was associated with significantly greater improvement in depressive symptoms than lamotrigine in a 25-week double blind extension of the 7-week acute phase study by Brown et al.<xref ref-type="bibr" rid="b78-ndt-5-369">78</xref>,<xref ref-type="bibr" rid="b79-ndt-5-369">79</xref> However, FLZ + OLZ was associated with more frequent weight gain and significantly higher incidence of clinically significant hypercholesterolemia (&#x02265;240 mg/dL) and weight gain (&#x02265;7% increase in weight from baseline) at the 25 week endpoint.<xref ref-type="bibr" rid="b79-ndt-5-369">79</xref> Overall, the state of the available evidence for FLX + OLZ therapy in bipolar depression is similar to that of the combination in TRD, with encouraging results shown in short-term acute phase studies, but limited longer-term data.</p><p>Enthusiasm is thus tempered by several unanswered questions regarding the use of FLX/OLZ augmentation in TRD. The optimal augmenting dose of OLZ has not been established, though anecdotal reports and uncontrolled evidence suggest that the target dose may be lower (2.5 to 10 mg) than those used in the treatment of schizophrenia or bipolar disorder.<xref ref-type="bibr" rid="b81-ndt-5-369">81</xref>,<xref ref-type="bibr" rid="b82-ndt-5-369">82</xref> The long-term efficacy and safety profile of FLX/OLZ in TRD has also not been established. There have been no controlled investigations longer than 12 weeks to date. As such, there are also no studies focused on the question of how long OLZ augmentation of FLX is required among patients who respond acutely to the combination.</p><p>The paucity of long-term studies is also of vital clinical interest because of concerns about body weight gain and dysmetabolic effects that are associated with OLZ. Of the antipsychotic drugs, OLZ is among the most orexigenic and, with the exception of clozapine, is associated with the greatest short-term weight gain and longer-term risk of hyperglycemia, diabetes, and atherogenic dyslipidemia.<xref ref-type="bibr" rid="b83-ndt-5-369">83</xref>&#x02013;<xref ref-type="bibr" rid="b85-ndt-5-369">85</xref> These metabolic risks must be carefully considered when deciding among the varied options available for augmentation of antidepressants in TRD. Apart from the obvious long-term health concerns, individuals with MDD are in physically poorer health than the general population<xref ref-type="bibr" rid="b86-ndt-5-369">86</xref> and therefore comprise a patient sub-population that is already at risk for profound cardiovascular morbidity and early mortality. Indeed, major depression has been identified as an independent risk factor for coronary artery disease and premature death due to cardiovascular causes.<xref ref-type="bibr" rid="b87-ndt-5-369">87</xref>&#x02013;<xref ref-type="bibr" rid="b89-ndt-5-369">89</xref> As is the case with schizophrenia and bipolar disorder, psychiatric illnesses that are associated with considerable physical health burden and early mortality due to cardiovascular disease,<xref ref-type="bibr" rid="b90-ndt-5-369">90</xref>,<xref ref-type="bibr" rid="b91-ndt-5-369">91</xref> use of OLZ for patients with major depression requires close metabolic monitoring and follow-up. The stringency of such monitoring should generally be the same that used for OLZ treatment of bipolar disorder and schizophrenia, even if lower doses of OLZ are shown to be effective for antidepressant augmentation.</p></sec><sec sec-type="intro|methods|discussion"><title>Characteristics and implications of study design and execution</title><p>The definition of TRD is a matter of ongoing debate, and numerous and varying criteria have been used to defined TRD samples in clinical trials.<xref ref-type="bibr" rid="b92-ndt-5-369">92</xref> To improve uniformity, several definitional models have been proposed, a detailed review of which will not be provided here. The interested reader is referred to several excellent reviews.<xref ref-type="bibr" rid="b93-ndt-5-369">93</xref>&#x02013;<xref ref-type="bibr" rid="b95-ndt-5-369">95</xref> For purposes of the current discussion, some design features and issues in study execution, many of which focus on sample selection and study definitions of TRD, may have led to the inclusion of less-treatment resistant depressed patients. This could have introduced bias toward null findings in some of the reviewed studies.</p><p>For example, two of the reviewed studies based their definition of TRD, in part, on a history of failure not confined to the current depressive episode.<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref>,<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> Only the studies by Shelton et al<xref ref-type="bibr" rid="b58-ndt-5-369">58</xref> and Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> randomized patients that had both a retrospective and prospective lead-in antidepressant failure in the current depressive episode. Only the Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> group randomized patients that had both a retrospective and prospective lead-in antidepressant failure in the current depressive episode only. Planned sub-group analyses of subjects in the Shelton et al<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> and Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> studies who met both retrospective and prospective TRD inclusion criteria for the current depressive episode revealed a more marked treatment effect for FLX/OLZ. In the Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> study, improvement in MADRS at study endpoint was significantly greater for FLX/OLZ compared with FLX alone in this patient subgroup. A pooled analysis of data from all of the above reviewed acute-phase studies was performed by Trivedi et al<xref ref-type="bibr" rid="b76-ndt-5-369">76</xref> which focused on only those subjects with a history of antidepressant non-response in the current depressive episode (N = 1146). FLX/OLZ was associated with significantly greater 8-week improvement in MADRS scores (&#x02013;13.0 vs &#x02013;8.6 vs &#x02013;8.2) and higher rates of remission (25.5% vs 17.3% vs 14.0%) compared with FLX or OLZ monotherapy.<xref ref-type="bibr" rid="b76-ndt-5-369">76</xref></p><p>Second, although a 4- to 6-week time interval for lead-in phase treatment could be considered generally adequate, many patients may require longer than this to adequately respond to antidepressant monotherapy,<xref ref-type="bibr" rid="b96-ndt-5-369">96</xref> a situation that may be even more problematic for drugs that require slower or more prolonged titration to therapeutic doses. These factors may have been particularly relevant for the Shelton et al <xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> and Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> studies, both of which utilized antidepressant medications during the lead-in phase that required titration to therapeutic doses (NTP and VLFX, respectively). Assuming that dosage adjustments were made during the first week even after achieving initial target doses, this would have left approximately 6 weeks of lead-in antidepressant treatment at adequate dosage. This time interval would not be sufficient to exclude late responders who, by definition, are not treatment-resistant but would have still been included in the double-blind acute treatment phase of these studies.</p><p>Third, investigators in the Shelton et al <xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> and Corya et al <xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> studies were not blinded to the double-blind acute phase entry criteria (reduction of &#x02265;30% in MADRS scores) which, as pointed out by the study authors, may have led to unconscious bias toward continued treatment and randomization via an under-rating of MADRS scores at the end of the lead-in phase. The lower than expected rates of partial treatment response at the end of the lead-in phase of both of these studies (18% and 26%, respectively) support this hypothesis; however, response rates for individuals with treatment resistant depression would also be expected to be low. In the study by Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> investigators were blinded to the double-blind acute phase study entry criteria. As such, the potential limitations posed by lack of blinding to acute phase study criteria do not apply to this study.</p><p>Fourth, in each of the reviewed studies, some patients who were eligible for double-blind acute phase treatment were re-randomized to the same antidepressant medication that they received during the lead-in period. These individuals would have received up to 15 weeks of NTP treatment in the Shelton et al<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref> study, up to 19 weeks of VLFX treatment in the Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref> study, and up to 16 weeks of FLX treatment in the Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref> study, thus causing an imbalance in study design and possible bias in favor of NTP, VLFX, or FLX, respectively. Finally, none of the reviewed studies included a placebo, as it was deemed unethical to deny active treatment to patients with refractory depression. Lack of a placebo group, however, makes it difficult to rule out non-pharmacological causes of clinical improvement across groups.</p></sec></sec><sec sec-type="conclusions"><title>Summary and conclusions</title><p>TRD represents a clinical challenge for which more effective treatments are urgently needed. The combination of FLX and OLZ has shown considerable promise in short-term, acute phase studies; however, little is known about the relative effectiveness of FLX/OLZ augmentation compared with other augmenting or combination strategies for TRD. Several questions remain concerning the optimal dosing and required duration of OLZ in combination with FLX for patients with TRD, and little is known about the long-term efficacy, tolerability and safety of this combination. This includes lack of data regarding long-term effects of FLX/OLZ on surrogate markers of cardiovascular risk (weight gain, dysglycemia, atherogenic dyslipidemia) and important clinical endpoints (eg, development of diabetes and serious cardiovascular disease). Future studies of comparative effectiveness of FLX/OLZ augmentation and other forms of combination therapy for TRD are needed in order to best determine its place among existing treatment options, either in the form of head-to-head comparisons with other TRD treatment options or as a therapeutic option in sequential treatment studies of patients with major depression.</p></sec></body><back><fn-group><fn><p><bold>Information sources</bold></p><p>PubMed, PsycINFO, Ovid MEDLINE, clinicaltrials.gov.</p></fn><fn><p><bold>Disclosures</bold></p><p>Dr Bobo has received grant/research support from Cephalon and has served on the speaker&#x02019;s bureau in the past for Pfizer and Janssen Pharmaceutica.</p><p>Dr Shelton has received grant/research support from Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, Inc., Sanofi-Aventis, Wyeth, Inc., AstraZeneca Pharmaceuticals, Forest Pharmaceuticals, Otsuka America, Inc., Pamlab, Inc., and Abbott Laboratories; has served as a paid consultant for Pfizer, Inc., Janssen Pharmaceutica, Eli Lilly and Co., Forest Pharmaceuticals, Otsuka America, Inc., Pamlab Inc., and Sierra Neuropharmaceuticals; and has served on the speaker&#x02019;s bureau in the past for Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica, Pfizer, Inc., GlaxoSmithKline, Wyeth, Inc., and Pamlab, Inc.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ndt-5-369"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>GI</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name></person-group><article-title>Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD</article-title><source>Eur Neuropsychopharmacol</source><year>2009</year><volume>19</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">18823760</pub-id></mixed-citation></ref><ref id="b2-ndt-5-369"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>RC</given-names></name></person-group><article-title>Treatment options for refractory depression</article-title><source>J Clin Psychiatry</source><year>1999</year><volume>60</volume><issue>Suppl 4</issue><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10086483</pub-id></mixed-citation></ref><ref id="b3-ndt-5-369"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>T</given-names></name><name><surname>Papakostas</surname><given-names>GI</given-names></name><name><surname>Posternak</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Empirical testing of two models for staging antidepressant treatment resistance</article-title><source>J Clin Psychopharmacol</source><year>2005</year><month>8</month><volume>25</volume><issue>4</issue><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">16012276</pub-id></mixed-citation></ref><ref id="b4-ndt-5-369"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>M</given-names></name><name><surname>Iskedjian</surname><given-names>M</given-names></name><name><surname>Ruiz</surname><given-names>I</given-names></name><name><surname>Einarson</surname><given-names>TR</given-names></name></person-group><article-title>Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials</article-title><source>Curr Med Res Opin</source><year>2006</year><volume>22</volume><issue>9</issue><fpage>1825</fpage><lpage>1837</lpage><pub-id pub-id-type="pmid">16968586</pub-id></mixed-citation></ref><ref id="b5-ndt-5-369"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>HJ</given-names></name></person-group><article-title>Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment</article-title><source>World J Biol Psychiatry</source><year>2008</year><volume>9</volume><issue>2</issue><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">18428079</pub-id></mixed-citation></ref><ref id="b6-ndt-5-369"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><issue>1</issue><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16390886</pub-id></mixed-citation></ref><ref id="b7-ndt-5-369"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><issue>11</issue><fpage>1905</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">17074942</pub-id></mixed-citation></ref><ref id="b8-ndt-5-369"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greden</surname><given-names>JF</given-names></name></person-group><article-title>The burden of disease for treatment-resistant depression</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62</volume><issue>Suppl 16</issue><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">11480881</pub-id></mixed-citation></ref><ref id="b9-ndt-5-369"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>MB</given-names></name><name><surname>Boland</surname><given-names>RJ</given-names></name></person-group><article-title>Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression</article-title><source>Biol Psychiatry</source><year>1998</year><volume>44</volume><issue>5</issue><fpage>348</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">9755357</pub-id></mixed-citation></ref><ref id="b10-ndt-5-369"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Friedman</surname><given-names>ES</given-names></name><name><surname>Biggs</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><issue>5</issue><fpage>739</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">17475733</pub-id></mixed-citation></ref><ref id="b11-ndt-5-369"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name></person-group><article-title>When at first you don&#x02019;t succeed: sequential strategies for antidepressant nonresponders</article-title><source>J Clin Psychiatry</source><year>1997</year><volume>58</volume><issue>Suppl 13</issue><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">9402916</pub-id></mixed-citation></ref><ref id="b12-ndt-5-369"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Medication augmentation after the failure of SSRIs for depression</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>12</issue><fpage>1243</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">16554526</pub-id></mixed-citation></ref><ref id="b13-ndt-5-369"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>RC</given-names></name><name><surname>Papakostas</surname><given-names>GI</given-names></name></person-group><article-title>Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder</article-title><source>Acta Psychiatr Scand</source><year>2008</year><volume>117</volume><issue>4</issue><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">18190674</pub-id></mixed-citation></ref><ref id="b14-ndt-5-369"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>GI</given-names></name><name><surname>Shelton</surname><given-names>RC</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name></person-group><article-title>Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><issue>6</issue><fpage>826</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">17592905</pub-id></mixed-citation></ref><ref id="b15-ndt-5-369"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyrka</surname><given-names>AR</given-names></name><name><surname>Price</surname><given-names>LH</given-names></name><name><surname>Mello</surname><given-names>MF</given-names></name><name><surname>Mello</surname><given-names>AF</given-names></name><name><surname>Carpenter</surname><given-names>LL</given-names></name></person-group><article-title>Psychotic major depression: a benefit-risk assessment of treatment options</article-title><source>Drug Saf</source><year>2006</year><volume>29</volume><issue>6</issue><fpage>491</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">16752932</pub-id></mixed-citation></ref><ref id="b16-ndt-5-369"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>JC</given-names></name><name><surname>Pikalov</surname><given-names>A</given-names></name><name><surname>Berman</surname><given-names>RM</given-names></name></person-group><article-title>Augmentation treatment in major depressive disorder: focus on aripiprazole</article-title><source>Neuropsychiatr Dis Treat</source><year>2008</year><volume>4</volume><issue>5</issue><fpage>937</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">19183784</pub-id></mixed-citation></ref><ref id="b17-ndt-5-369"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name><name><surname>Keating</surname><given-names>GM</given-names></name></person-group><article-title>Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression</article-title><source>Drugs</source><year>2008</year><volume>68</volume><issue>8</issue><fpage>1115</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">18484802</pub-id></mixed-citation></ref><ref id="b18-ndt-5-369"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jans</surname><given-names>LA</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Markus</surname><given-names>CR</given-names></name><name><surname>Blokland</surname><given-names>A</given-names></name></person-group><article-title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</article-title><source>Mol Psychiatry</source><year>2007</year><volume>12</volume><issue>6</issue><fpage>522</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">17160067</pub-id></mixed-citation></ref><ref id="b19-ndt-5-369"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schidkraut</surname><given-names>JJ</given-names></name></person-group><article-title>The catecholamine hypothesis of affective disorders: a review of supporting evidence</article-title><source>Am J Psychiatry</source><year>1965</year><volume>122</volume><fpage>509</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">5319766</pub-id></mixed-citation></ref><ref id="b20-ndt-5-369"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhwuegi</surname><given-names>AS</given-names></name></person-group><article-title>Central monoamines and their role in major depression</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2004</year><volume>28</volume><issue>3</issue><fpage>435</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">15093950</pub-id></mixed-citation></ref><ref id="b21-ndt-5-369"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richelson</surname><given-names>E</given-names></name></person-group><article-title>Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>Suppl 13</issue><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">14552650</pub-id></mixed-citation></ref><ref id="b22-ndt-5-369"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotti</surname><given-names>M</given-names></name><name><surname>Mayberg</surname><given-names>HS</given-names></name><name><surname>McGinnis</surname><given-names>S</given-names></name><name><surname>Brannan</surname><given-names>SL</given-names></name><name><surname>Jerabek</surname><given-names>P</given-names></name></person-group><article-title>Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><issue>11</issue><fpage>1830</fpage><lpage>1840</lpage><pub-id pub-id-type="pmid">12411216</pub-id></mixed-citation></ref><ref id="b23-ndt-5-369"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayberg</surname><given-names>HS</given-names></name><name><surname>Liotti</surname><given-names>M</given-names></name><name><surname>Brannan</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness</article-title><source>Am J Psychiatry</source><year>1999</year><volume>156</volume><issue>5</issue><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">10327898</pub-id></mixed-citation></ref><ref id="b24-ndt-5-369"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drevets</surname><given-names>WC</given-names></name><name><surname>Bogers</surname><given-names>W</given-names></name><name><surname>Raichle</surname><given-names>ME</given-names></name></person-group><article-title>Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism</article-title><source>Eur Neuropsychopharmacol</source><year>2002</year><volume>12</volume><issue>6</issue><fpage>527</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12468016</pub-id></mixed-citation></ref><ref id="b25-ndt-5-369"><label>25</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Marek</surname><given-names>G</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Kaplan</surname><given-names>GB</given-names></name><name><surname>Hammer</surname><given-names>RP</given-names></name></person-group><article-title>Neural circuitry and signaling in depression</article-title><source>Brain Circuitry and Signaling in Psychiatry</source><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Publishing, Inc</publisher-name><year>2002</year><fpage>153</fpage><lpage>178</lpage></mixed-citation></ref><ref id="b26-ndt-5-369"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>ND</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Brammer</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy</article-title><source>Biol Psychiatry</source><year>2007</year><volume>1;62</volume><issue>11</issue><fpage>1236</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">17601497</pub-id></mixed-citation></ref><ref id="b27-ndt-5-369"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishizaki</surname><given-names>J</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Mimura</surname><given-names>M</given-names></name></person-group><article-title>Changes in regional cerebral blood flow following antidepressant treatment in late-life depression</article-title><source>Int J Geriatr Psychiatry</source><year>2008</year><volume>23</volume><issue>8</issue><fpage>805</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">18214999</pub-id></mixed-citation></ref><ref id="b28-ndt-5-369"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlassenko</surname><given-names>A</given-names></name><name><surname>Sheline</surname><given-names>YI</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name></person-group><article-title>Cerebral perfusion response to successful treatment of depression with different serotoninergic agents</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2004</year><volume>16</volume><issue>3</issue><fpage>360</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">15377745</pub-id></mixed-citation></ref><ref id="b29-ndt-5-369"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>KR</given-names></name><name><surname>Jones</surname><given-names>IK</given-names></name><name><surname>Barnes</surname><given-names>A</given-names></name><name><surname>Pilowsky</surname><given-names>LS</given-names></name></person-group><article-title>Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression</article-title><source>Am J Psychiatry</source><year>2003</year><volume>160</volume><issue>2</issue><fpage>374</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">12562589</pub-id></mixed-citation></ref><ref id="b30-ndt-5-369"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatsumi</surname><given-names>M</given-names></name><name><surname>Groshan</surname><given-names>K</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Richelson</surname><given-names>E</given-names></name></person-group><article-title>Pharmacological profile of antidepressants and related compounds at human monoamine transporters</article-title><source>Eur J Pharmacol</source><year>1997</year><volume>340</volume><issue>2&#x02013;3</issue><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">9537821</pub-id></mixed-citation></ref><ref id="b31-ndt-5-369"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusack</surname><given-names>B</given-names></name><name><surname>Nelson</surname><given-names>A</given-names></name><name><surname>Richelson</surname><given-names>E</given-names></name></person-group><article-title>Binding of antidepressants to human brain receptors: focus on newer generation compounds</article-title><source>Psychopharmacology (Berl)</source><year>1994</year><volume>114</volume><issue>4</issue><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">7855217</pub-id></mixed-citation></ref><ref id="b32-ndt-5-369"><label>32</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>JF</given-names></name><name><surname>Tollefson</surname><given-names>GD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Schatzbert</surname><given-names>AF</given-names></name><name><surname>Nemeroff</surname><given-names>CB</given-names></name></person-group><article-title>Fluoxetine</article-title><source>Textbook of Psychopharmacology</source><edition>Third Edition ed</edition><publisher-loc>Arlington, VA</publisher-loc><publisher-name>American Psychiatric Publishing, Inc</publisher-name><year>2004</year><fpage>231</fpage><lpage>246</lpage></mixed-citation></ref><ref id="b33-ndt-5-369"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>ST</given-names></name><name><surname>de</surname><given-names>MC</given-names></name><name><surname>Blier</surname><given-names>P</given-names></name></person-group><article-title>Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers</article-title><source>Br J Pharmacol</source><year>1999</year><volume>126</volume><issue>3</issue><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">10188964</pub-id></mixed-citation></ref><ref id="b34-ndt-5-369"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodero</surname><given-names>AP</given-names></name><name><surname>Valdomero</surname><given-names>A</given-names></name><name><surname>Cuadra</surname><given-names>GR</given-names></name><name><surname>Ramirez</surname><given-names>OA</given-names></name><name><surname>Orsingher</surname><given-names>OA</given-names></name></person-group><article-title>Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>503</volume><issue>1&#x02013;3</issue><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15496293</pub-id></mixed-citation></ref><ref id="b35-ndt-5-369"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>CH</given-names></name><name><surname>Ritchie</surname><given-names>JC</given-names></name><name><surname>Boss-Williams</surname><given-names>KA</given-names></name><name><surname>Weiss</surname><given-names>JM</given-names></name></person-group><article-title>Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons</article-title><source>Int J Neuropsychopharmacol</source><year>2009</year><volume>12</volume><issue>5</issue><fpage>627</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">18950545</pub-id></mixed-citation></ref><ref id="b36-ndt-5-369"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>ST</given-names></name><name><surname>Blier</surname><given-names>P</given-names></name></person-group><article-title>Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons</article-title><source>Brain Res</source><year>2001</year><volume>922</volume><issue>1</issue><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11730697</pub-id></mixed-citation></ref><ref id="b37-ndt-5-369"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prisco</surname><given-names>S</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name></person-group><article-title>Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area</article-title><source>Br J Pharmacol</source><year>1995</year><volume>116</volume><issue>2</issue><fpage>1923</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">8528581</pub-id></mixed-citation></ref><ref id="b38-ndt-5-369"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMascio</surname><given-names>M</given-names></name><name><surname>DiGiovanni</surname><given-names>G</given-names></name><name><surname>DiMatteo</surname><given-names>V</given-names></name><name><surname>Prisco</surname><given-names>S</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area</article-title><source>Brain Res Bull</source><year>1998</year><volume>46</volume><issue>6</issue><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">9744293</pub-id></mixed-citation></ref><ref id="b39-ndt-5-369"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiGiovanni</surname><given-names>G</given-names></name><name><surname>DeDeurwaerdere</surname><given-names>P</given-names></name><name><surname>DiMascio</surname><given-names>M</given-names></name><name><surname>DiMatteo</surname><given-names>V</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name><name><surname>Spampinato</surname><given-names>U</given-names></name></person-group><article-title>Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study</article-title><source>Neuroscience</source><year>1999</year><volume>91</volume><issue>2</issue><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">10366016</pub-id></mixed-citation></ref><ref id="b40-ndt-5-369"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMatteo</surname><given-names>V</given-names></name><name><surname>DiGiovanni</surname><given-names>G</given-names></name><name><surname>DiMascio</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name></person-group><article-title>SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system</article-title><source>Neuropharmacology</source><year>1999</year><volume>38</volume><issue>8</issue><fpage>1195</fpage><lpage>1205</lpage><pub-id pub-id-type="pmid">10462132</pub-id></mixed-citation></ref><ref id="b41-ndt-5-369"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMatteo</surname><given-names>V</given-names></name><name><surname>DiGiovanni</surname><given-names>G</given-names></name><name><surname>DiMascio</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name></person-group><article-title>Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens</article-title><source>Neuropharmacology</source><year>1998</year><volume>37</volume><issue>2</issue><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">9680252</pub-id></mixed-citation></ref><ref id="b42-ndt-5-369"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blier</surname><given-names>P</given-names></name><name><surname>Szabo</surname><given-names>ST</given-names></name></person-group><article-title>Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>66</volume><issue>Suppl 8</issue><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16336034</pub-id></mixed-citation></ref><ref id="b43-ndt-5-369"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seager</surname><given-names>MA</given-names></name><name><surname>Huff</surname><given-names>KD</given-names></name><name><surname>Barth</surname><given-names>VN</given-names></name><name><surname>Phebus</surname><given-names>LA</given-names></name><name><surname>Rasmussen</surname><given-names>K</given-names></name></person-group><article-title>Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity</article-title><source>Biol Psychiatry</source><year>2004</year><volume>55</volume><issue>11</issue><fpage>1103</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">15158430</pub-id></mixed-citation></ref><ref id="b44-ndt-5-369"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobert</surname><given-names>A</given-names></name><name><surname>Rivet</surname><given-names>JM</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><etal/></person-group><article-title>Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat</article-title><source>Synapse</source><year>2000</year><volume>36</volume><issue>3</issue><fpage>205</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">10819900</pub-id></mixed-citation></ref><ref id="b45-ndt-5-369"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>J</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Bonaccorso</surname><given-names>S</given-names></name><name><surname>Fowler</surname><given-names>WL</given-names></name><name><surname>O&#x02019;Laughlin</surname><given-names>IA</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group><article-title>5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release</article-title><source>J Neurochem</source><year>2001</year><volume>76</volume><issue>5</issue><fpage>1521</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">11238736</pub-id></mixed-citation></ref><ref id="b46-ndt-5-369"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liegeois</surname><given-names>JF</given-names></name><name><surname>Ichikawa</surname><given-names>J</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group><article-title>5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner</article-title><source>Brain Res</source><year>2002</year><volume>947</volume><issue>2</issue><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">12176156</pub-id></mixed-citation></ref><ref id="b47-ndt-5-369"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>J</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group><article-title>R(+)-8-OH-DPAT, a serotonin (1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>291</volume><issue>3</issue><fpage>1227</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">10565846</pub-id></mixed-citation></ref><ref id="b48-ndt-5-369"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jentsch</surname><given-names>JD</given-names></name><name><surname>Roth</surname><given-names>RH</given-names></name><name><surname>Taylor</surname><given-names>JR</given-names></name></person-group><article-title>Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action</article-title><source>Prog Brain Res</source><year>2000</year><volume>126</volume><fpage>433</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">11105661</pub-id></mixed-citation></ref><ref id="b49-ndt-5-369"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisstaub</surname><given-names>NV</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Lira</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice</article-title><source>Science</source><year>2006</year><volume>313</volume><issue>5786</issue><fpage>536</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">16873667</pub-id></mixed-citation></ref><ref id="b50-ndt-5-369"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feiger</surname><given-names>AD</given-names></name><name><surname>Heiser</surname><given-names>JF</given-names></name><name><surname>Shrivastava</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>3</issue><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">12716264</pub-id></mixed-citation></ref><ref id="b51-ndt-5-369"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>PJ</given-names></name><name><surname>Stewart</surname><given-names>JW</given-names></name><name><surname>Quitkin</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement</article-title><source>J Clin Psychopharmacol</source><year>1994</year><volume>14</volume><issue>5</issue><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">7806692</pub-id></mixed-citation></ref><ref id="b52-ndt-5-369"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barde</surname><given-names>YA</given-names></name></person-group><article-title>Neurotrophins: a family of proteins supporting the survival of neurons</article-title><source>Prog Clin Biol Res</source><year>1994</year><volume>390</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">7724649</pub-id></mixed-citation></ref><ref id="b53-ndt-5-369"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinowich</surname><given-names>K</given-names></name><name><surname>Manji</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>New insights into BDNF function in depression and anxiety</article-title><source>Nat Neurosci</source><year>2007</year><volume>10</volume><issue>9</issue><fpage>1089</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">17726474</pub-id></mixed-citation></ref><ref id="b54-ndt-5-369"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Monteggia</surname><given-names>LM</given-names></name></person-group><article-title>A neurotrophic model for stress-related mood disorders</article-title><source>Biol Psychiatry</source><year>2006</year><volume>59</volume><issue>12</issue><fpage>1116</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">16631126</pub-id></mixed-citation></ref><ref id="b55-ndt-5-369"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Duman</surname><given-names>R</given-names></name><name><surname>Sanacora</surname><given-names>G</given-names></name></person-group><article-title>Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications</article-title><source>Biol Psychiatry</source><year>2008</year><volume>64</volume><issue>6</issue><fpage>527</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">18571629</pub-id></mixed-citation></ref><ref id="b56-ndt-5-369"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castren</surname><given-names>E</given-names></name><name><surname>Voikar</surname><given-names>V</given-names></name><name><surname>Rantamaki</surname><given-names>T</given-names></name></person-group><article-title>Role of neurotrophic factors in depression</article-title><source>Curr Opin Pharmacol</source><year>2007</year><volume>7</volume><issue>1</issue><fpage>18</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">17049922</pub-id></mixed-citation></ref><ref id="b57-ndt-5-369"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name></person-group><article-title>Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine</article-title><source>Brain Res</source><year>2004</year><volume>1025</volume><issue>1&#x02013;2</issue><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15464760</pub-id></mixed-citation></ref><ref id="b58-ndt-5-369"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>RC</given-names></name><name><surname>Tollefson</surname><given-names>GD</given-names></name><name><surname>Tohen</surname><given-names>M</given-names></name><etal/></person-group><article-title>A novel augmentation strategy for treating resistant major depression</article-title><source>Am J Psychiatry</source><year>2001</year><volume>158</volume><issue>1</issue><fpage>131</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">11136647</pub-id></mixed-citation></ref><ref id="b59-ndt-5-369"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Asberg</surname><given-names>M</given-names></name></person-group><article-title>A new depression scale designed to be sensitive to change</article-title><source>Br J Psychiatry</source><year>1979</year><volume>134</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">444788</pub-id></mixed-citation></ref><ref id="b60-ndt-5-369"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><article-title>A rating scale for depression</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1960</year><volume>23</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14399272</pub-id></mixed-citation></ref><ref id="b61-ndt-5-369"><label>61</label><mixed-citation publication-type="book"><collab>Clinical Global Impressions</collab><person-group person-group-type="editor"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><source>ECDEU Assessment Manual for Psychopharmacology</source><year>1976</year><publisher-loc>Rockville, MD</publisher-loc><publisher-name>U.S. Department of Health, Education, and Welfare</publisher-name><comment>DHEW Publication No. (ADM) 76&#x02013;338</comment></mixed-citation></ref><ref id="b62-ndt-5-369"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>RC</given-names></name><name><surname>Williamson</surname><given-names>DJ</given-names></name><name><surname>Corya</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>66</volume><issue>10</issue><fpage>1289</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">16259543</pub-id></mixed-citation></ref><ref id="b63-ndt-5-369"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corya</surname><given-names>SA</given-names></name><name><surname>Williamson</surname><given-names>D</given-names></name><name><surname>Sanger</surname><given-names>TM</given-names></name><name><surname>Briggs</surname><given-names>SD</given-names></name><name><surname>Case</surname><given-names>M</given-names></name><name><surname>Tollefson</surname><given-names>G</given-names></name></person-group><article-title>A randomized, double-blind comparison of olanzapine/ fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression</article-title><source>Depress Anxiety</source><year>2006</year><volume>23</volume><issue>6</issue><fpage>364</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">16710853</pub-id></mixed-citation></ref><ref id="b64-ndt-5-369"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Corya</surname><given-names>SA</given-names></name><name><surname>Osuntokun</surname><given-names>O</given-names></name><etal/></person-group><article-title>A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><issue>2</issue><fpage>224</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">17335320</pub-id></mixed-citation></ref><ref id="b65-ndt-5-369"><label>65</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><article-title>Hamiton Anxiety Scale</article-title><source>ECDEU Assessment Manual for Psychopharmacology</source><fpage>193</fpage><lpage>198</lpage><year>1976</year><publisher-loc>Rockville, MD</publisher-loc><publisher-name>U.S. Department of Health, Education, and Welfare</publisher-name></mixed-citation></ref><ref id="b66-ndt-5-369"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Harnett-Sheehan</surname><given-names>K</given-names></name><name><surname>Raj</surname><given-names>BA</given-names></name></person-group><article-title>The measurement of disability</article-title><source>Int Clin Psychopharmacol</source><year>1996</year><volume>11</volume><issue>Suppl 3</issue><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">8923116</pub-id></mixed-citation></ref><ref id="b67-ndt-5-369"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corya</surname><given-names>SA</given-names></name><name><surname>Andersen</surname><given-names>SW</given-names></name><name><surname>Detke</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>11</issue><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">14658950</pub-id></mixed-citation></ref><ref id="b68-ndt-5-369"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>GM</given-names></name><name><surname>Angus</surname><given-names>JW</given-names></name></person-group><article-title>A rating scale for extrapyramidal side effects</article-title><source>Acta Psychiatr Scand Suppl</source><year>1970</year><volume>212</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">4917967</pub-id></mixed-citation></ref><ref id="b69-ndt-5-369"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>TR</given-names></name></person-group><article-title>A rating scale for drug-induced akathisia</article-title><source>Br J Psychiatry</source><year>1989</year><volume>154</volume><fpage>672</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">2574607</pub-id></mixed-citation></ref><ref id="b70-ndt-5-369"><label>70</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><article-title>Abnormal Involuntary Movement Scale (AIMS)</article-title><source>ECDEU Assessment Manual for Psychopharmacology</source><fpage>534</fpage><lpage>537</lpage><year>1976</year><publisher-loc>Rockville, MD</publisher-loc><publisher-name>National Institute for Mental Health</publisher-name></mixed-citation></ref><ref id="b71-ndt-5-369"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>RM</given-names></name><name><surname>Marcus</surname><given-names>RN</given-names></name><name><surname>Swanink</surname><given-names>R</given-names></name><etal/></person-group><article-title>The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><issue>6</issue><fpage>843</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">17592907</pub-id></mixed-citation></ref><ref id="b72-ndt-5-369"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>RN</given-names></name><name><surname>McQuade</surname><given-names>RD</given-names></name><name><surname>Carson</surname><given-names>WH</given-names></name><etal/></person-group><article-title>The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study</article-title><source>J Clin Psychopharmacol</source><year>2008</year><volume>28</volume><issue>2</issue><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">18344725</pub-id></mixed-citation></ref><ref id="b73-ndt-5-369"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name></person-group><article-title>Quetiapine monotherapy for bipolar depression</article-title><source>Neuropsychiatr Dis Treat</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18728771</pub-id></mixed-citation></ref><ref id="b74-ndt-5-369"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>EJ</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name></person-group><article-title>A review of quetiapine in combination with antidepressant therapy in patients with depression</article-title><source>Neuropsychiatr Dis Treat</source><year>2007</year><volume>3</volume><issue>6</issue><fpage>855</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">19300621</pub-id></mixed-citation></ref><ref id="b75-ndt-5-369"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group><article-title>Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility</article-title><source>Expert Rev Neurother</source><year>2008</year><volume>8</volume><issue>9</issue><fpage>1299</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">18759541</pub-id></mixed-citation></ref><ref id="b76-ndt-5-369"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Osuntokun</surname><given-names>O</given-names></name><etal/></person-group><article-title>An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression</article-title><source>J Clin Psychiatry</source><year>2009</year><volume>70</volume><issue>3</issue><fpage>387</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">19284928</pub-id></mixed-citation></ref><ref id="b77-ndt-5-369"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohen</surname><given-names>M</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Calabrese</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression</article-title><source>Arch Gen Psychiatry</source><year>2003</year><volume>60</volume><issue>11</issue><fpage>1079</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">14609883</pub-id></mixed-citation></ref><ref id="b78-ndt-5-369"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>EB</given-names></name><name><surname>McElroy</surname><given-names>SL</given-names></name><name><surname>Keck</surname><given-names>PE</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression</article-title><source>J Clin Psychiatry</source><year>2006</year><volume>67</volume><issue>7</issue><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">16889444</pub-id></mixed-citation></ref><ref id="b79-ndt-5-369"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Dunner</surname><given-names>DL</given-names></name><name><surname>McElroy</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression</article-title><source>Int J Neuropsychopharmacol</source><year>2008</year><month>12</month><day>11</day><fpage>1</fpage><lpage>10</lpage><comment>[Epub ahead of print]</comment></mixed-citation></ref><ref id="b80-ndt-5-369"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>JD</given-names></name><name><surname>Shults</surname><given-names>J</given-names></name></person-group><article-title>Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression &#x02013; lack of manic induction</article-title><source>J Affect Disord</source><year>2005</year><volume>87</volume><issue>1</issue><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">15923042</pub-id></mixed-citation></ref><ref id="b81-ndt-5-369"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kamata</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>H</given-names></name><name><surname>Ishigooka</surname><given-names>J</given-names></name></person-group><article-title>Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series</article-title><source>Hum Psychopharmacol</source><year>2008</year><volume>23</volume><issue>3</issue><fpage>217</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">18172909</pub-id></mixed-citation></ref><ref id="b82-ndt-5-369"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>K</given-names></name></person-group><article-title>Creating more effective antidepressants: clues from the clinic</article-title><source>Drug Discov Today</source><year>2006</year><volume>11</volume><issue>13&#x02013;14</issue><fpage>623</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">16793531</pub-id></mixed-citation></ref><ref id="b83-ndt-5-369"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>DB</given-names></name><name><surname>Mentore</surname><given-names>JL</given-names></name><name><surname>Heo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antipsychotic-induced weight gain: a comprehensive research synthesis</article-title><source>Am J Psychiatry</source><year>1999</year><volume>156</volume><issue>11</issue><fpage>1686</fpage><lpage>1696</lpage><pub-id pub-id-type="pmid">10553730</pub-id></mixed-citation></ref><ref id="b84-ndt-5-369"><label>84</label><mixed-citation publication-type="journal"><collab>American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity</collab><article-title>Consensus development conference on antipsychotic drugs and obesity and diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>596</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">14747245</pub-id></mixed-citation></ref><ref id="b85-ndt-5-369"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcomer</surname><given-names>JW</given-names></name></person-group><article-title>Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review</article-title><source>CNS Drugs</source><year>2005</year><volume>19</volume><issue>Suppl 1</issue><fpage>1</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15998156</pub-id></mixed-citation></ref><ref id="b86-ndt-5-369"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iosifescu</surname><given-names>DV</given-names></name></person-group><article-title>Treating depression in the medically ill</article-title><source>Psychiatr Clin North Am</source><year>2007</year><volume>30</volume><issue>1</issue><fpage>77</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17362805</pub-id></mixed-citation></ref><ref id="b87-ndt-5-369"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lett</surname><given-names>HS</given-names></name><name><surname>Blumenthal</surname><given-names>JA</given-names></name><name><surname>Babyak</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment</article-title><source>Psychosom Med</source><year>2004</year><volume>66</volume><issue>3</issue><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">15184688</pub-id></mixed-citation></ref><ref id="b88-ndt-5-369"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>KW</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report</article-title><source>Psychosom Med</source><year>2006</year><volume>68</volume><issue>5</issue><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">17012516</pub-id></mixed-citation></ref><ref id="b89-ndt-5-369"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frasure-Smith</surname><given-names>N</given-names></name><name><surname>Lesperance</surname><given-names>F</given-names></name></person-group><article-title>Depression--a cardiac risk factor in search of a treatment</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>23</issue><fpage>3171</fpage><lpage>3173</lpage><pub-id pub-id-type="pmid">12813125</pub-id></mixed-citation></ref><ref id="b90-ndt-5-369"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group><article-title>Prevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular disease</article-title><source>CNS Spectr</source><year>2008</year><volume>13</volume><issue>6 Suppl 10</issue><fpage>9</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">18567981</pub-id></mixed-citation></ref><ref id="b91-ndt-5-369"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roshanaei-Moghaddam</surname><given-names>B</given-names></name><name><surname>Katon</surname><given-names>W</given-names></name></person-group><article-title>Premature mortality from general medical illnesses among persons with bipolar disorder: a review</article-title><source>Psychiatr Serv</source><year>2009</year><volume>60</volume><issue>2</issue><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">19176408</pub-id></mixed-citation></ref><ref id="b92-ndt-5-369"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlim</surname><given-names>MT</given-names></name><name><surname>Turecki</surname><given-names>G</given-names></name></person-group><article-title>What is the meaning of treatment resistant/ refractory major depression (TRD)? A systematic review of current randomized trials</article-title><source>Eur Neuropsychopharmacol</source><year>2007</year><volume>17</volume><issue>11</issue><fpage>696</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">17521891</pub-id></mixed-citation></ref><ref id="b93-ndt-5-369"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>MB</given-names></name></person-group><article-title>Issues in treatment-resistant depression</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>66</volume><issue>Suppl 8</issue><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16336031</pub-id></mixed-citation></ref><ref id="b94-ndt-5-369"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Dube</surname><given-names>S</given-names></name></person-group><article-title>Research issues in the study of difficult-to-treat depression</article-title><source>Biol Psychiatry</source><year>2003</year><volume>53</volume><issue>8</issue><fpage>743</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">12706958</pub-id></mixed-citation></ref><ref id="b95-ndt-5-369"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sackeim</surname><given-names>HA</given-names></name></person-group><article-title>The definition and meaning of treatment-resistant depression</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62</volume><issue>Suppl 16</issue><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">11480879</pub-id></mixed-citation></ref><ref id="b96-ndt-5-369"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Morris</surname><given-names>DW</given-names></name><name><surname>Grannemann</surname><given-names>BD</given-names></name><name><surname>Mahadi</surname><given-names>S</given-names></name></person-group><article-title>Symptom clusters as predictors of late response to antidepressant treatment</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>66</volume><issue>8</issue><fpage>1064</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">16086624</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="f1-ndt-5-369" position="float"><label>Figure 1</label><caption><p>Basic design features of acute phase studies of combined fluoxetine and olanzapine (FLX/OLZ) in treatment resistant depression. <xref ref-type="bibr" rid="b58-ndt-5-369">58</xref>,<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref>&#x02013;<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref></p><p><bold>Abbreviations:</bold> FLX, fluoxetine; FLX (cont), FLX treatment continued into double-blind study phase; FLX/OLZ, fluoxetine + olanzapine combination therapy; NTP, nortriptyline; NTP (cont), NTP treatment continued into double-blind study phase; PLC, placebo; VLFX, venlafaxine.</p></caption><graphic xlink:href="ndt-5-369f1"/></fig><table-wrap id="t1-ndt-5-369" position="float"><label>Table 1</label><caption><p>Selected serotonergic neuroreceptor targets of olanzapine with potential relevance for antidepressant augmentation in treatment-resistant depression<xref ref-type="bibr" rid="b13-ndt-5-369">13</xref>,<xref ref-type="bibr" rid="b42-ndt-5-369">42</xref>,<xref ref-type="bibr" rid="b45-ndt-5-369">45</xref>&#x02013;<xref ref-type="bibr" rid="b47-ndt-5-369">47</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Neuroreceptor</th><th align="left" valign="top" rowspan="1" colspan="1">Pharmacological activity</th><th align="left" valign="top" rowspan="1" colspan="1">Functional consequence</th><th align="left" valign="top" rowspan="1" colspan="1">Possible benefit in TRD</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">5-HT1A</td><td align="left" valign="top" rowspan="1" colspan="1">Agonist</td><td align="left" valign="top" rowspan="1" colspan="1">Enhance NE release in PFC and NAcc</td><td align="left" valign="top" rowspan="1" colspan="1">Improved cognitive functioning</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Increase DA release in frontal cortex and NAcc</td><td align="left" valign="top" rowspan="1" colspan="1">Improved mood, cognitive functioning and motivational drive</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Overcome SSRI induced suppression of central DA activity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5-HT2A</td><td align="left" valign="top" rowspan="1" colspan="1">Antagonist</td><td align="left" valign="top" rowspan="1" colspan="1">Enhance 5-HT and NE release<xref ref-type="table-fn" rid="tfn1-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Reverse SSRI induced suppression of locus coeruleus firing</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Enhance DA release in PFC<xref ref-type="table-fn" rid="tfn2-ndt-5-369">b</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Improved regulation of mood and cognitive functioning</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Overcome SSRI induced suppression of central DA activity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5-HT2C</td><td align="left" valign="top" rowspan="1" colspan="1">Antagonist</td><td align="left" valign="top" rowspan="1" colspan="1">Enhance NE release in PFC and NAcc</td><td align="left" valign="top" rowspan="1" colspan="1">Improved cognitive functioning</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Increase DA release in frontal cortex and NAcc</td><td align="left" valign="top" rowspan="1" colspan="1">Improved mood, cognitive functioning and motivational drive</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Overcome SSRI induced suppression of central DA activity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5-HT6</td><td align="left" valign="top" rowspan="1" colspan="1">Antagonist</td><td align="left" valign="top" rowspan="1" colspan="1">Enhance DA release in PFC</td><td align="left" valign="top" rowspan="1" colspan="1">Improved cognitive functioning</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Overcome SSRI induced suppression of central DA activity</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ndt-5-369"><label>a</label><p>In presence of 5-HT reuptake inhibition.</p></fn><fn id="tfn2-ndt-5-369"><label>b</label><p>In presence of weak D2 receptor antagonism.</p></fn><fn id="tfn3-ndt-5-369"><p><bold>Abbreviations:</bold> TRD, treatment-resistant depression; DA, dopamine; NE, norepinephrine; PFC, ; SSRI, selective serotonin reuptake inhibitor; NAcc,;</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ndt-5-369" position="float"><label>Table 2</label><caption><p>Definition of treatment-resistant depression and characteristics of lead-in phase</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Study</th><th align="left" valign="top" rowspan="1" colspan="1">Diagnosis</th><th align="left" valign="top" rowspan="1" colspan="1">Retrospective failure</th><th align="left" valign="top" rowspan="1" colspan="1">Prospective failure (lead-in)</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">Mean/mean modal dose (mg/day)</th><th align="left" valign="top" rowspan="1" colspan="1">No. (%)responders (lead-in)</th><th align="left" valign="top" rowspan="1" colspan="1">No. (%)randomized to double-blind treatment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Shelton et al<xref ref-type="bibr" rid="b58-ndt-5-369">58</xref></td><td align="left" valign="top" rowspan="1" colspan="1">DSM-IV (MDD, recurrent, without psychotic features)</td><td align="left" valign="top" rowspan="1" colspan="1">Failure to respond to AD of two or more different classes (one non-SSRI), each &#x02265;4 weeks, at &#x0201c;acceptable&#x0201d; doses, current episode</td><td align="left" valign="top" rowspan="1" colspan="1">Open-label FLX (20&#x02013;60 mg/day), 6 weeks 
<break/>Response = Reduction in HAM-D-21 score by &#x02265;30%</td><td align="left" valign="top" rowspan="1" colspan="1">34</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (82.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shelton et al<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref></td><td align="left" valign="top" rowspan="1" colspan="1">DSM-IV (MDD, without psychotic features) with SCID-I confirmation</td><td align="left" valign="top" rowspan="1" colspan="1">Past failure to respond to SSRI (&#x02265;4 week trial), at therapeutic doses<xref ref-type="table-fn" rid="tfn4-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Open-label trial of NTP (75&#x02013;175 mg/day), 7 weeks 
<break/>Response = Reduction in MADRS score by &#x02265;30%</td><td align="left" valign="top" rowspan="1" colspan="1">946</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">167 (17.7)</td><td align="left" valign="top" rowspan="1" colspan="1">500 (52.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref></td><td align="left" valign="top" rowspan="1" colspan="1">DSM-IV (MDD, single episode or recurrent, without psychotic features)</td><td align="left" valign="top" rowspan="1" colspan="1">Past failure to respond to SSRI (&#x02265;6 week trial), at therapeutic doses<xref ref-type="table-fn" rid="tfn4-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Open-label trial of VLFX (75&#x02013;375 mg/day), 7 weeks 
<break/>Response = Reduction in MADRS score by &#x02265;30%</td><td align="left" valign="top" rowspan="1" colspan="1">807</td><td align="left" valign="top" rowspan="1" colspan="1">226 &#x000b1; 100</td><td align="left" valign="top" rowspan="1" colspan="1">200 (26.3)</td><td align="left" valign="top" rowspan="1" colspan="1">483 (59.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref></td><td align="left" valign="top" rowspan="1" colspan="1">DSM-IV (MDD, recurrent, without psychotic features) with SCID-I confirmation</td><td align="left" valign="top" rowspan="1" colspan="1">Failure to respond to non-SSRI AD (&#x02265;6 weeks), at therapeutic doses,<xref ref-type="table-fn" rid="tfn5-ndt-5-369">b</xref> current episode</td><td align="left" valign="top" rowspan="1" colspan="1">Open-label trial of FLX (50 mg/day), 8 weeks 
<break/>Response = Reduction in HAM-D-17 by &#x02265;25% or HAM-D &#x0003c;18 or a &#x0003e;15% decrease between weeks 7 and 8</td><td align="left" valign="top" rowspan="1" colspan="1">1, 313</td><td align="left" valign="top" rowspan="1" colspan="1">47.4 &#x000b1; 9.3</td><td align="left" valign="top" rowspan="1" colspan="1">338 (28.9)</td><td align="left" valign="top" rowspan="1" colspan="1">605 (46.1)</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ndt-5-369"><label>a</label><p>Defined as citalopram 40 mg/day, fluoxetine 40 mg/day, paroxetine 40 mg/day, or sertraline 150 mg/day.</p></fn><fn id="tfn5-ndt-5-369"><label>b</label><p>Defined as paroxetine 40 mg/day, venlafaxine 150 mg/day, bupropion 300 mg/day, or trazodone 450 mg/day.</p></fn><fn id="tfn6-ndt-5-369"><label>c</label><p>Excluding patients who did not complete at least 5 weeks of open-label fluoxetine treatment.</p></fn><fn id="tfn7-ndt-5-369"><p><bold>Abbreviations:</bold> AD, antidepressant; DSM-IV, Diagnostic and Statistical Manual for Mental Disorders, 4th Edition; FLX, fluoxetine; HAM-D, Hamilton-Depression Rating Scale (17 or 21 item scale); MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; NR, not reported; NTP, nortriptyline; SCID, Structured Clinical Interview for the DSM; SSRI, selective serotonin reuptake inhibitor; VLFX, venlafaxine.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ndt-5-369" position="float"><label>Table 3</label><caption><p>Characteristics of studies of combined fluoxetine and olanzapine in treatment-resistant major depression</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Study<xref ref-type="table-fn" rid="tfn8-ndt-5-369">a</xref></th><th colspan="3" align="left" valign="top" rowspan="1">Study design
<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">Medication use
<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">Outcomes
<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Design</th><th align="left" valign="top" rowspan="1" colspan="1">Duration</th><th align="left" valign="top" rowspan="1" colspan="1">Randomization/blinding</th><th align="left" valign="top" rowspan="1" colspan="1">Comparator groups, N, dose</th><th align="left" valign="top" rowspan="1" colspan="1">Additional medications</th><th align="left" valign="top" rowspan="1" colspan="1">Outcome measures</th><th align="left" valign="top" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Shelton et al<xref ref-type="bibr" rid="b58-ndt-5-369">58</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Double- blind RCT</td><td align="left" valign="top" rowspan="1" colspan="1">8 weeks</td><td align="left" valign="top" rowspan="1" colspan="1">Described/not described</td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ, N = 10, 52.0/13.5 mg/day
<break/>FLX, N = 10, 52.0 mg/day
<break/>OLZ, N = 8, 12.5 mg/day</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; MADRS
<break/>&#x00394; HAM-D
<break/>&#x00394; CGI-D
<break/>Response<xref ref-type="table-fn" rid="tfn9-ndt-5-369">b</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ &#x0003e; FLX and OLZ
<break/>FLX/OLZ &#x0003e; OLZ
<break/>FLX/OLZ &#x0003e; OLZ
<break/>FLX/OLZ &#x0003e; OLZ</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shelton et al<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Double- blind RCT</td><td align="left" valign="top" rowspan="1" colspan="1">8 weeks</td><td align="left" valign="top" rowspan="1" colspan="1">Described/described</td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ, N = 146, 8.5/35.6 mg/day
<break/>FLX, N = 142, 35.8 mg/day
<break/>OLZ, N = 144, 8.3 mg/day
<break/>NTP, N = 68, 103.5 mg/day<xref ref-type="table-fn" rid="tfn10-ndt-5-369">c</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Lorazepam PRN, up to 2 mg/day)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; MADRS
<break/>&#x00394; HAM-A
<break/>&#x00394; CGI-S
<break/>Response<xref ref-type="table-fn" rid="tfn9-ndt-5-369">b</xref><break/>Remission<xref ref-type="table-fn" rid="tfn11-ndt-5-369">d</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ &#x0003e; NTP (weeks 1&#x02013;4)
<break/>FLX/OLZ &#x0003e; FLX (weeks 2&#x02013;5)
<break/>FLX/OLZ &#x0003e; OLZ (weeks 2, 4, 6, 7)
<break/>No significant between groups difference
<break/>FLX/OLZ &#x0003e; OLZ (week 8)
<break/>No significant between groups difference
<break/>No significant between groups difference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Double- blind RCT</td><td align="left" valign="top" rowspan="1" colspan="1">12 weeks</td><td align="left" valign="top" rowspan="1" colspan="1">Described/described</td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ, N = 243, fixed doses
<break/>FLX, N = 60, 37.5 mg/day
<break/>OLZ, N = 62, 7.9 mg/day
<break/>VLFX, N = 59, 275.4 mg/day
<break/>OFC 1/5, N = 59, 1.0/5.0 mg/day<xref ref-type="table-fn" rid="tfn12-ndt-5-369">e</xref></td><td align="left" valign="top" rowspan="1" colspan="1">BZD PRN, up to equivalent of LOR 4 mg/day</td><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; MADRS
<break/>CGI-D
<break/>HAM-A
<break/>Response<xref ref-type="table-fn" rid="tfn9-ndt-5-369">b</xref><break/>Remission<xref ref-type="table-fn" rid="tfn11-ndt-5-369">d</xref><break/>BZD use</td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ &#x0003e; OLZ (weeks 1&#x02013;12)
<break/>FLX/OLZ &#x0003e; FLX (weeks 1&#x02013;11)
<break/>FLX/OLZ &#x0003e; VLFX (weeks 1&#x02013;6)
<break/>FLX/OLZ &#x0003e; OLZ
<break/>FLX/OLZ &#x0003e; OLZ
<break/>FLX/OLZ &#x0003e; OLZ
<break/>FLX/OLZ &#x0003e; OLZ
<break/>FLX &#x0003e; FLX/OLZ</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref>, <xref ref-type="table-fn" rid="tfn13-ndt-5-369">f</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Double- blind RCT</td><td align="left" valign="top" rowspan="1" colspan="1">8 weeks</td><td align="left" valign="top" rowspan="1" colspan="1">Described/described</td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ, N = 198, 8.6/48.8 mg/day
<break/>FLX, N = 203, 49.5 mg/day
<break/>OLZ, N = 197, 8.7 mg/day</td><td align="left" valign="top" rowspan="1" colspan="1">BZD allowed, dose unspecified</td><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; MADRS
<break/>Response<xref ref-type="table-fn" rid="tfn9-ndt-5-369">b</xref><break/>Remission<xref ref-type="table-fn" rid="tfn14-ndt-5-369">g</xref><break/>Time to response
<break/>Time to remission
<break/>Onset of action<xref ref-type="table-fn" rid="tfn15-ndt-5-369">h</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ &#x0003e; FLX and OLZ
<break/>FLX/OLZ &#x0003e; FLX and OLZ
<break/>FLX/OLZ &#x0003e; FLX and OLZ
<break/>Time required for 25% of patients to achieve response: FLX/OLZ (30 days)
<break/>&#x0003c;FLX (55 days) and OLZ (53 days)
<break/>Time required for 25% of patients to achieve remission: FLX/OLZ (52 days)
<break/>&#x0003c;FLX (71 days)
<break/>FLX/OLZ (6.4 days) = OLZ (6.8 days)
<break/>&#x0003c;FLX (10.0 days)</td></tr></tbody></table><table-wrap-foot><fn id="tfn8-ndt-5-369"><label>a</label><p><bold>Notes:</bold> All studies were supported or sponsored by Eli Lilly and Company.</p></fn><fn id="tfn9-ndt-5-369"><label>b</label><p>Categorical treatment responder defined as a &#x02265; 50% improvement in MADRS scores from baseline.</p></fn><fn id="tfn10-ndt-5-369"><label>c</label><p>Mean (SD) NTP plasma level by study visit ranged from 87.9 &#x000b1; 37.5 ng/L to 114.5 &#x000b1; 31.2 ng/L.</p></fn><fn id="tfn11-ndt-5-369"><label>d</label><p>Categorical remitter status defined as two consecutive MADRS total scores &#x02264; 8.</p></fn><fn id="tfn12-ndt-5-369"><label>e</label><p>There were 5 dosing arms for FLX/OLZ. The highest 4 doses were pooled. The lowest dose, OLZ 1/5 (OLZ 1 mg/FLX 5 mg), was used as a control group.</p></fn><fn id="tfn13-ndt-5-369"><label>f</label><p>Randomized, double-blind trial was run as two identical concurrent studies. Pooled results are reported in Table Y.</p></fn><fn id="tfn14-ndt-5-369"><label>g</label><p>Categorical remission status defined as MADRS total score &#x02264; 10 at study endpoint.</p></fn><fn id="tfn15-ndt-5-369"><label>h</label><p>Onset of action was defined as time required for 50% of patients to achieve a &#x02265; 25% reduction in MADRS total score from baseline</p></fn><fn id="tfn16-ndt-5-369"><p><bold>Abbreviations:</bold> BPRS, Brief Psychiatric Rating Scale; BZD, benzodiazepine; CGI-D, Clinical Global Impressions-Depression scale; CGI-S, Clinical Global Impressions-Severity scale; FLX, fluoxetine; FLX/OLZ, fluoxetine + olanzapine combination therapy; HAM-A, Hamilton Anxiety Scale; LOR, lorazepam; MADRS, Montgomery-Asberg Depression Rating Scale; NTP, nortriptyline; OLZ, olanzapine; VLFX, venlafaxine.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ndt-5-369" position="float"><label>Table 4</label><caption><p>Treatment-emergent adverse effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Discontinuation due to TEAEs, no. (%)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x00394; weight (kg), mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">SWG (%)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x00394; total cholesterol (mmol/L), mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x00394; triglycerides (mmol/L), mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x00394; PRL (nmol/L), mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Glucose (mg/dL)</th><th align="left" valign="top" rowspan="1" colspan="1">EPS</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Shelton et al<xref ref-type="bibr" rid="b58-ndt-5-369">58</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ (N = 10)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">+6.7 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">FLX (N = 10)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">+0.9 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">OLZ (N = 8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (25)</td><td align="left" valign="top" rowspan="1" colspan="1">+6.1 (2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shelton et al<xref ref-type="bibr" rid="b62-ndt-5-369">62</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ (N = 146)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (6.8)</td><td align="left" valign="top" rowspan="1" colspan="1">+3.3 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7.8</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.36</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+0.36</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">FLX (N = 142)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.42 (2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.06</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+0.05</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">OLZ (N = 144)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">+2.9 (3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4.3</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+0.26</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NTP (N = 68)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">+0.2 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.03</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn17-ndt-5-369">a</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corya et al<xref ref-type="bibr" rid="b63-ndt-5-369">63</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ (N = 243)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+4.3 (4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.24</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn18-ndt-5-369">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">FLX (N = 60)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.04</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn18-ndt-5-369">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">OLZ (N = 62)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+3.5 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.09</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn18-ndt-5-369">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">VLFX (N = 59)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.05</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn18-ndt-5-369">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">OFC 1/5 (N = 59)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn18-ndt-5-369">b</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thase et al<xref ref-type="bibr" rid="b64-ndt-5-369">64</xref></td><td align="left" valign="top" rowspan="1" colspan="1">FLX/OLZ (N = 198)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (13.5)</td><td align="left" valign="top" rowspan="1" colspan="1">+4.9 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.84 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">+ 2.2 (6.8)</td><td align="left" valign="top" rowspan="1" colspan="1">+0.15 (0.5)<xref ref-type="table-fn" rid="tfn19-ndt-5-369">c</xref></td><td align="left" valign="top" rowspan="1" colspan="1">+0.78 (2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn20-ndt-5-369">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">FLX (N = 203)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">+0.4 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.04 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.88 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">+0.04 (0.3)<xref ref-type="table-fn" rid="tfn19-ndt-5-369">c</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.17 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn20-ndt-5-369">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">OLZ (N = 197)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">+5.5 (3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+ 0.15 (34.0)</td><td align="left" valign="top" rowspan="1" colspan="1">+ 2.9 (10.2)</td><td align="left" valign="top" rowspan="1" colspan="1">+0.22 (0.7)<xref ref-type="table-fn" rid="tfn19-ndt-5-369">c</xref></td><td align="left" valign="top" rowspan="1" colspan="1">+0.46 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">ND<xref ref-type="table-fn" rid="tfn20-ndt-5-369">d</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn17-ndt-5-369"><label>a</label><p>No significant differences between comparator groups. Values not reported.</p></fn><fn id="tfn18-ndt-5-369"><label>b</label><p>No significant changes from baseline were observed. Values not reported.</p></fn><fn id="tfn19-ndt-5-369"><label>c</label><p>Original results reported in micrograms/L. Conversion to nmol/L was based on an estimated molecular weight of 23,000 Da for PRL (Sinha, 1995).</p></fn><fn id="tfn20-ndt-5-369"><label>d</label><p>No significant increases in measures of EPS from baseline in FLX/OLZ group. EPS measures for FLX/OLZ group reported as similar to that of OLZ group. Results of comparisons with FLX not provided. Values not reported.</p></fn><fn id="tfn21-ndt-5-369"><p><bold>Abbreviations:</bold> TEAES, treatment-emergent adverse effects; &#x02013;, not reported; EPS, extrapyramidal side effects; FLX, fluoxetine; FLX/OLZ, combined fluoxetine + olanzapine; ND, no significant differences between comparator groups were reported (see text); NTP, nortriptyline; OFC 1/5, low-dose olanzapine (1 mg) + fluoxetine (5 mg); PRL, prolactin concentration; SWG, substantial weight gain (defined as an increase in weight &#x02265; 10% from baseline); VLFX, venlafaxine.</p></fn></table-wrap-foot></table-wrap></floats-group></article>